Paolo Silvani and Anna Camporesi Pages 129 - 133 ( 5 )
Persistent pulmonary hypertension (PPHN) is a disease characterised by the disruption of the transition from fetal to neonatal circulation with the persistence of high pulmonary vascular resistances and right-to left shunting. This condition, occurring in about 1-2 newborns per 1000 live births, causes severe hypoxemia. Despite significant improvements in treatment, the mortality of PPHN varies from 10 to 20 % of affected newborns. Pulmonary hypertension is frequently observed in some cardiac malformation and in congenital diaphragmatic hernia, in meconium aspiration syndrome, neonatal sepsis, podalic presentation and male sex. Maternal risk factors are tobacco smoking, cesarean section, low socioeconomic conditions, diabetes and urinary infections. Another predisposing condition is antenatal or postnatal exposure to some drugs. The medications involved in drug-induced pulmonary hypertension and the mechanisms involved are reviewed.
Pulmonary hypertension, newborn, persistent pulmonary hypertension of the newborn, non-steroidal antiinflammatory agents, serotonin-reuptake inhibitors, octreotide, diazoxide
Dipartimento di Anestesia e Rianimazione, Ospedale dei Bambini “V. Buzzi”, Via Castelvetro 32, 20154 Milano, Italy.